Literature DB >> 14529287

Fatty acid-binding proteins inhibit hydration of epoxyeicosatrienoic acids by soluble epoxide hydrolase.

Richard L Widstrom1, Andrew W Norris, Jon Van Der Veer, Arthur A Spector.   

Abstract

Epoxyeicosatrienoic acids (EETs) are potent regulators of vascular homeostasis and are bound by cytosolic fatty acid-binding proteins (FABPs) with K(d) values of approximately 0.4 microM. To determine whether FABP binding modulates EET metabolism, we examined the effect of FABPs on the soluble epoxide hydrolase (sEH)-mediated conversion of EETs to dihydroxyeicosatrienoic acids (DHETs). Kinetic analysis of sEH conversion of racemic [(3)H]11,12-EET yielded K(m) = 0.45 +/- 0.08 microM and V(max) = 9.2 +/- 1.4 micromol min(-1) mg(-)(1). Rat heart FABP (H-FABP) and rat liver FABP were potent inhibitors of 11,12-EET and 14,15-EET conversion to DHET. The resultant inhibition curves were best described by a substrate depletion model, with K(d) = 0.17 +/- 0.01 microM for H-FABP binding to 11,12-EET, suggesting that FABP acts by reducing EET availability to sEH. The EET depletion by FABP was antagonized by the co-addition of arachidonic acid, oleic acid, linoleic acid, or 20-hydroxyeicosatetraenoic acid, presumably due to competitive displacement of FABP-bound EET. Collectively, these findings imply that FABP might potentiate the actions of EETs by limiting their conversion to DHET. However, the effectiveness of this process may depend on metabolic conditions that regulate the levels of competing FABP ligands.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14529287     DOI: 10.1021/bi034971d

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  13 in total

Review 1.  EET signaling in cancer.

Authors:  Dipak Panigrahy; Emily R Greene; Ambra Pozzi; Dao Wen Wang; Darryl C Zeldin
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

2.  Chiral lipidomics of monoepoxy and monohydroxy metabolites derived from long-chain polyunsaturated fatty acids.

Authors:  Maximilian Blum; Inci Dogan; Mirjam Karber; Michael Rothe; Wolf-Hagen Schunck
Journal:  J Lipid Res       Date:  2018-11-08       Impact factor: 5.922

Review 3.  Epoxides and soluble epoxide hydrolase in cardiovascular physiology.

Authors:  John D Imig
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

4.  Interaction of epoxyeicosatrienoic acids and adipocyte fatty acid-binding protein in the modulation of cardiomyocyte contractility.

Authors:  V Lamounier-Zepter; C Look; W-H Schunck; I Schlottmann; C Woischwill; S R Bornstein; A Xu; I Morano
Journal:  Int J Obes (Lond)       Date:  2014-11-05       Impact factor: 5.095

Review 5.  Epoxyeicosatrienoic acid analogs and vascular function.

Authors:  V Sudhahar; S Shaw; J D Imig
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

Review 6.  Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism.

Authors:  Arthur A Spector; Hee-Yong Kim
Journal:  Biochim Biophys Acta       Date:  2014-08-02

Review 7.  Arachidonic acid cytochrome P450 epoxygenase pathway.

Authors:  Arthur A Spector
Journal:  J Lipid Res       Date:  2008-10-23       Impact factor: 5.922

Review 8.  Cytochrome P450-derived eicosanoids: the neglected pathway in cancer.

Authors:  Dipak Panigrahy; Arja Kaipainen; Emily R Greene; Sui Huang
Journal:  Cancer Metastasis Rev       Date:  2010-12       Impact factor: 9.264

9.  Hydrolysis of cis- and trans-epoxyeicosatrienoic acids by rat red blood cells.

Authors:  Houli Jiang; Angela G Zhu; Magdalena Mamczur; Christophe Morisseau; Bruce D Hammock; John R Falck; John C McGiff
Journal:  J Pharmacol Exp Ther       Date:  2008-04-29       Impact factor: 4.030

Review 10.  Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases.

Authors:  John D Imig; Bruce D Hammock
Journal:  Nat Rev Drug Discov       Date:  2009-10       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.